Javed Butler describes the main findings from the Phase IIa CardioCell’s Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy. He also outlines the main challenges of cardiovascular therapies in cancer patients.
ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients
Dai congressiNewsCARDIOINFO@ESC2016
Scelti dall'editore
- Joint AHA/Italian Federation of Cardiology Session
Nel corso dell’edizione 2014 delle Sessioni Scientifiche dell’American Heart Association si è tenuta la sessione…
- Un’altra pagina del Pennsylvania Chapter all’American College of Cardiology Meeting di San Diego
Come tradizione anche quest’anno si è tenuto nel corso dell’American College of Cardiology Meeting il…